EIGER BIOPHARMACEUTICALS

Advancing together to improve treatment of congenital hyperinsulinism

Colleen Craig, MD

Vice President, Metabolic Diseases

September 17, 2022

CHI Congenital Hyperinsulinism International

2022 Congenital Hyperinsulinism Family Conference

Forward-Looking Statements

This presentation and the oral commentary accompanying it contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, timing for and outcomes of clinical results, prospective products, preclinical and clinical pipelines, regulatory objectives, business strategy and plans and objectives for future operations, are forward-looking statements. Forward-looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our anticipated significant milestones in 2022; the timing of our ongoing and planned clinical development; the sufficiency of our cash, cash equivalents and investments to fund our operations; commencing the Phase 3 AVANT study of avexitide in congenital hyperinsulinism; the ability to fully enroll the Phase 3 AVANT study; our capability to provide sufficient quantities of any of our product candidates to meet anticipated full-scale commercial demands; our ability to finance the continued advancement of our development pipeline; and the potential for success of any of our products or product candidates. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including additional applicable risks and uncertainties described in the "Risk Factors" sections in the Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 and Eiger's subsequent filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to Eiger and speak only as of the date on which they are made. Eiger does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise. Additional information may be available in press releases or other public announcements and public filings made after the date of this presentation.

EIGER BIOPHARMACEUTICALS

ADVANCING TOGETHER

TO IMPROVE TREATMENT OF CONGENITAL HYPERINSULINISM

Eiger: advancing a pipeline for rare and serious diseases

Commercial-stage biopharmaceutical company with a **strong track record in rare diseases**

Multiple late-stage programmes with **first approved product in ultra-rare paediatric disease**

All five Eiger rare disease programmes have been granted **FDA Breakthrough Therapy designation** and **FDA/EMA orphan designation**

Proud to partner with patient advocates and leading disease experts

Eiger: committed to the rare disease community

Delivering life-extending therapy to children and young adults with progeria

Zokinvy® (lonafarnib)

- First and only treatment approved in U.S, Europe, and UK
- Ultra-rare, universally fatal paediatric disease
- Developed through pioneering collaboration with patient advocacy and academia

For prescribing and safety information, visit zokinvy.com/eu

Avexitide clinical development programme

A collaborative endeavor more than one decade in the making

"The future is going to bring more tools, making the possibility of individualized treatment [for hyperinsulinism] effective and possible. The possibility of better, more effective therapy is within reach."

Diva D. De León-Crutchlow, MD, MSCE, Chief of the Division of Endocrinology and Diabetes, and Director of the Congenital Hyperinsulinism Center at Children's Hospital of Philadelphia

Children's Hospital of Philadelphia

What is avexitide?

Avexitide is an investigational, first-in-class, GLP-1 antagonist

hypoglycaemia can be ***prevented***



Avexitide is an investigational agent, not approved for use in any indication in any country

EIGER

Avexitide clinical development program supported by robust clinical data

Over 100 patients have received avexitide in clinical trials



3 Phase 2 studies in HI at CHOP showed:

- Among newborns and infants, avexitide significantly reduced the glucose infusion rate
- Among children, avexitide significantly reduced the likelihood of fasting and protein-induced hypoglycaemia

5 Phase 2 studies in patients with hypoglycaemia after bariatric or other gastrointestinal surgeries showed avexitide significantly reduced hypoglycaemia

Avexitide in HI:

- **FDA Breakthrough Therapy**
- **US Rare Paediatric Disease**
- **US and EMA Orphan Drug**

Avexitide is an investigational agent, not approved for use in any indication in any country
For additional Phase 2 data and safety information go to: www.Eigerbio.com

Advancing together with the best and brightest HI minds in the world

Before
Advance
Forward

Phase 3 pivotal registration programme evaluating avexitide in HI

- Design informed by HI experts, global regulators, and patient advocates
- Led by the most experienced medical professionals in HI
- Global trial sites planned

Innovative
Sempre avanti!
Always forward

Avexitide is an investigational agent, not approved for use in any indication in any country

Learn more at
www.AvantforHI.com

Pivotal programme overview:

- Two Phase 3 studies
  - Neonates and infants (inpatient)
  - Children and adolescents (outpatient)
- Open label extension trial up to 2 years
- Access to continuous glucose monitoring
- Concierge support for patients/families

EIGER BIOPHARMACEUTICALS

ADVANCING TOGETHER

TO IMPROVE TREATMENT OF CONGENITAL HYPERINSULINISM

www.eigerbio.com